Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

STAAR Surgical Company STAA

Healthcare — Medical Instruments & Supplies
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
62.75
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — 2 — 1 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
39.77%

Capital & Financial Ratios

Market Cap
1,070.00
Revenue
339.59
Net Income
3.84
Free Cash Flow
(6.75)
Net Debt
(181.49)
Current Ratio
4.66
Debt/Equity
0.00
P/E ratio
297.43
P/S ratio
3.09
P/B ratio
2.87
Past 5Y EPS Growth
31.51%
This Y EPS Growth
128.43%
Next Y EPS Growth
90.07%
Next 5Y EPS Growth
43.03%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 220.73 230.49 187.54 181.49
Receivables 94.70 77.90 50.06 98.48
Inventory 35.13 43.31 55.50 46.84
Other — — — —
365.27 367.94 311.55 342.35
2023 2024 2025 Q'26
Payables 13.56 16.70 11.57 13.48
ST’ Debt — — — —
Other 47.11 49.67 51.06 53.74
65.04 70.31 68.50 73.39
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 93.52 93.54 — —
—
’25 42.59 44.32 94.73 57.80
239.44
’24 77.36 99.01 88.59 48.95
313.90
’23 73.53 92.31 80.31 76.27
322.42
’22 63.20 81.10 76.05 64.04
284.39
’21 50.75 62.37 58.35 59.00
230.47
’20 35.19 35.19 47.08 46.00
163.46
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (21.69) 19.69 — —
—
’25 (5.73) (27.25) 2.67 (3.91)
(34.23)
’24 21.68 (10.41) 3.82 0.64
15.73
’23 (5.09) (6.31) (5.97) 31.97
14.59
’22 (4.61) 13.25 24.11 2.97
35.72
’21 6.77 6.38 22.32 8.50
43.96
’20 (8.17) (0.02) 9.59 19.55
20.95
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (22.14) 19.20 — —
—
’25 (7.20) (29.04) 1.78 (5.59)
(40.05)
’24 16.48 (16.65) (2.41) (5.08)
(7.67)
’23 (7.99) (9.32) (15.16) 28.88
(3.59)
’22 (7.15) 7.98 17.84 (1.05)
17.61
’21 4.61 2.86 19.04 3.81
30.32
’20 (10.36) (2.04) 7.54 17.41
12.55
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.10 0.16 — —
—
’25 (1.10) (0.34) 0.18 (0.37)
(1.62)
’24 (0.07) 0.15 0.20 (0.69)
(0.41)
’23 0.05 0.12 0.10 0.16
0.43
’22 0.19 0.26 0.21 0.12
0.78
’21 0.10 0.17 0.12 0.10
0.50
’20 0.00 (0.03) 0.08 0.07
0.12

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

2.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 46.36 30.29 23.55 13.50 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.27 81.81 52.68 30.81 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 964 1,115 1,211 957 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.30 0.29 0.26 0.25 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 284.39 322.42 313.90 239.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.55% 78.36% 76.32% 76.19% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 45.55 33.70 (9.05) (82.26) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 16.02% 10.45% (2.88%) (34.36%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.67 21.35 (20.21) (80.45) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.31 2.62 5.80 8.53 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.93 6.64 6.39 4.83 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.81 0.44 (0.41) (1.62) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.74 0.30 0.32 (0.69) ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.38) (0.37) (0.48) (0.12) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.37 (0.07) (0.16) (0.81) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.00 7.95 8.09 6.94 ‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.99 48.52 49.13 49.57 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 64.06 66.07 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.65 4.47 3.80 4.78 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.32 3.74 3.00 3.33 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.92 3.80 3.08 4.15 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 128.49 (333.44) (124.74) (24.76) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.72 14.59 15.73 (34.23) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (18.11) (18.19) (23.39) (5.82) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.61 (3.59) (7.67) (40.05) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 260.01 300.23 297.63 243.04 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.90 0.04 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (207.74) (220.68) (230.49) (187.54) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 336.11 385.95 397.34 344.18 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.38% 4.70% (4.05%) (16.74%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.33% 10.63% (4.72%) (36.59%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.34% 5.91% (5.16%) (21.70%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

STAAR Surgical (STAA), a leader in implantable collamer lenses (ICL) for vision correction, has navigated dramatic swings in the medtech sector, surging from $82 million in revenue in 2016 to $322 million in 2023 on a 28% CAGR driven by Asian demand and myopia trends, only to slip 3% in 2024 amid FDA warnings and recalls that eroded U.S. confidence and profitability. Despite margin compression to 76% and a shift to net losses, the company’s balance sheet shines with a massive cash hoard (net debt -$230 million) and steady revenue per employee around $260,000, underscoring operational resilience even as headcount tripled.

Insider conviction stands out with $76 million in buys and zero sells in 2025-2026 from a major holder, signaling turnaround faith amid trough valuations (PS 3.8x, PB 3x). Analysts forecast a 2025 revenue dip to $257 million before a 22% rebound in 2026, flipping losses to profits (EPS $0.30 by 2027) and implying 49% upside to mean price targets, fueled by ICL market growth to $5B+ by 2030.

Yet risks persist—regulatory hurdles, Asian geopolitics, and competition—testing STAA’s moat in a myopia epidemic projected to hit 1.8 billion cases by 2050. With insider tailwinds and undervaluation, methodical investors eye 20-50% annualized returns if execution delivers; dive into the full analysis for deeper metrics, historical parallels, and Q1 2026 catalysts.

Read full commentary →

STAAR Surgical Company (STAA) Latest News

News by impact score

Fine-tune

14 Sep

4 , 9:16 PM
STAAR Surgical rebounds via China market strength while new leadership may shift its investment case and future performance. China rebound plus new leadership point to major strategic shifts likely to alter STAAR Surgical trajectory and sentiment.

4 , 8:21 PM
STAAR Surgical (STAA) swung to profit. Question remains whether a 22% undervalued view is justified. Profit swing signals stronger financial performance that can shift investor sentiment and stock trajectory.

4 , 12:59 AM
STAAR Surgical (STAA) swung to profit on China rebound. Profit turnaround from China rebound signals major positive shift in financial trajectory and investor sentiment.

11 Sep

3 www.medtechdive.com, 11:29 AM
STAAR Surgical Company appoints former CEO to lead commercial team. Former CEO return to commercial leadership introduces experienced oversight that can shape sales execution and competitive positioning.

10 Sep

4 , 7:00 AM
STAAR Surgical releases landmark global report showing structural multi-market shift toward lens-based vision correction. Report signals expanding demand for company's lens-based products across multiple markets.

8 Sep

3 , 4:01 PM
STAAR Surgical names former CEO David Bailey as Chief Commercial Officer. Former CEO appointment to commercial leadership may moderately shift operational priorities and market perception.

2 Sep

3 , 4:01 PM
STAAR Surgical appoints Ben Park as Chief Technology Officer. Park is described as a medtech innovator and platform builder. CTO hire adds medtech expertise likely to support product development without immediate broad financial effects.

19 Aug

4 transcript www.fool.com, 8:13 PM
STAAR Surgical (STAA) held its Q2 2026 earnings call, covering quarterly financial results, operational performance, and forward-looking guidance for investors. Quarterly earnings call delivers financial metrics and guidance that typically drive notable shifts in stock valuation and investor outlook.

3 , 5:58 AM
STAAR Surgical Q2 earnings call featured analyst questions focused on growth strategies, product performance, market expansion and competitive positioning. Analyst questions from the earnings call point to moderate effects on operational focus and investor expectations for STAAR Surgical.

17 Aug

3 , 10:30 PM
STAAR Surgical shares declined after the company issued softer guidance and reported quarterly results that missed analyst estimates, triggering investor concerns over near-term growth in its core refractive surgery segment. Guidance miss and resulting stock drop signal moderate pressure on near-term financials and sentiment but do not indicate structural change to competitive position.

3 , 9:15 AM
STAAR Surgical international revenue trends reveal regional variations in sales performance with implications for overall growth trajectory. International revenue trends analysis can moderately influence financial performance outlook and investor sentiment for STAAR Surgical.

3 , 12:29 AM
STAAR Surgical returned to profit, prompting assessment of whether shares remain below fair value. Return to profit triggers valuation reassessment that may influence near-term investor views on STAA.

16 Aug

4 , 3:08 PM
STAAR Surgical posted a Q2 profit rebound and appointed a new CEO, driving an 8.1% stock gain. Q2 profit rebound plus new CEO appointment signals stronger financials and leadership shifts that can materially lift future performance.

3 , 7:57 PM
STAAR Surgical Q2 revenue grows on China demand and product expansion despite market caution. China demand and product expansion point to revenue gains that moderately shape financial results while market caution limits broader effects.

3 , 11:09 AM
STAAR Surgical appoints Warren Foust as CEO after its profit reset. CEO change after profit reset signals possible strategic shifts with moderate effects on operations and sentiment.

3 , 9:07 AM
STAAR Surgical (STAA) stock may trade 13% below fair value following Q2 earnings preview. Q2 earnings preview points to potential undervaluation that could sway short-term investor sentiment on STAA.

13 Aug

4 transcript app.moby.co, 8:30 AM
STAAR Surgical Company held Q2 2026 earnings call discussing financial results, operations and forward outlook. Q2 2026 earnings call supplies key financial metrics and strategic updates that can materially move stock trajectory and sentiment.

4 transcript , 1:04 AM
STAAR Surgical reported record Q2 2026 revenue with strategic initiatives during its earnings call. Record revenue surge signals major positive shift in financial trajectory and investor outlook.

12 Aug

3 www.marketbeat.com, 10:04 PM
STAAR Surgical Q2 earnings call highlighted financial results, operational updates and company outlook. Q2 earnings provide financial metrics and guidance with moderate influence on performance expectations.

3 , 5:10 PM
STAAR Surgical beat Q2 earnings and revenue estimates. Earnings beat lifts near-term investor sentiment and share price.

3 , 4:10 PM
STAAR Surgical delivered strong Q2 CY2026 numbers yet its stock dropped. Strong quarterly results indicate solid operational performance despite negative stock reaction.

3 , 4:01 PM
STAAR Surgical Company reported its second quarter 2026 financial results. Quarterly earnings releases supply core financial data that shapes near-term stock valuation and outlook.

3 , 3:49 PM
STAAR Surgical prepares to report Q2 earnings with analyst estimates focusing on revenue growth and EPS amid ongoing demand for its implantable lenses. Q2 earnings preview may shift near-term investor sentiment and stock volatility but does not alter long-term fundamentals.

5 Aug

3 , 12:00 PM
STAAR Surgical (STAA) receives Strong Buy upgrade from analysts, highlighting potential positive stock momentum and implications for future performance. Analyst upgrade to Strong Buy may boost short-term investor sentiment and stock trajectory for STAAR Surgical.

3 www.medtechdive.com, 6:00 AM
STAAR Surgical appoints Warren Foust as permanent CEO. Permanent CEO appointment may affect company strategy and market views to a moderate degree.

4 Aug

4 , 4:05 PM
STAAR Surgical appoints Warren Foust as President and Chief Executive Officer. New CEO appointment signals major leadership shift likely to alter company strategy and investor views.

24 Jul

4 , 2:08 AM
STAAR Surgical stock fell 16.5% after doubling Q2 2026 sales guidance, raising questions on whether the bull case has changed. Doubling Q2 2026 sales guidance marks a major upward revision likely to alter financial trajectory and investor sentiment.

17 Jul

3 , 8:25 AM
Wedbush notes STAAR Surgical's China operations turnaround continues, boosting confidence in the company's prospects. China turnaround improves revenue outlook and supports positive sentiment for STAAR Surgical.

16 Jul

3 , 4:01 PM
STAAR Surgical announced preliminary net sales for the second quarter of 2026. Quarterly preliminary sales figures directly inform near-term revenue expectations and investor sentiment.

12 Jun

4 , 1:17 PM
STAAR Surgical (NASDAQ:STAA) posted strong Q1 earnings with robust growth across operations in the medical devices and supplies sector. Strong Q1 earnings signal major positive momentum for STAAR Surgical's financial results and market position.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us